In8bio Inc Total Liabilities
In8bio Inc total liabilities. Based on the latest financial reports, In8bio Inc (INAB) has total liabilities worth $3.38 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See In8bio Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of In8bio Inc (2018–2025)
Total liabilities of In8bio Inc from 2018 to 2025. This chart illustrates how In8bio Inc's total liabilities have evolved over time, based on quarterly financial data.
In8bio Inc Competitors by Total Liabilities
The table below lists competitors of In8bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vanadium Resources Ltd
AU:VR8
|
Australia | AU$536.13K |
|
Reach Resources Ltd
AU:RR1
|
Australia | AU$471.57K |
|
Seacera Group Bhd
KLSE:7073
|
Malaysia | RM130.81 Million |
|
Micronet Ltd
TA:MCRNT
|
Israel | ILA612.00K |
|
Praxis Home Retail Limited
NSE:PRAXIS
|
India | Rs2.60 Billion |
|
Kodi-M Co Ltd
KQ:224060
|
Korea | ₩69.73 Billion |
|
Eastern International Ltd.
NASDAQ:ELOG
|
USA | $17.09 Million |
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
USA | $3.20 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down In8bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see INAB asset base.
Liquidity & Leverage Metrics
In8bio Inc Total Liabilities Ratios Explained
In8bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how In8bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for In8bio Inc (2018–2025)
The table below shows the annual total liabilities of In8bio Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.72 Million | -26.94% |
| 2024-12-31 | $6.47 Million | -26.29% |
| 2023-12-31 | $8.77 Million | -14.89% |
| 2022-12-31 | $10.31 Million | +155.12% |
| 2021-12-31 | $4.04 Million | +56.04% |
| 2020-12-31 | $2.59 Million | +75.41% |
| 2019-12-31 | $1.48 Million | +18.27% |
| 2018-12-31 | $1.25 Million | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more